Skip to main content
. 2012 Apr;14(4):304–314. doi: 10.1111/j.1463-1326.2011.01523.x

Figure 1.

Figure 1

LEAD-5 trial: mean HbA1c change (%) from baseline over time (last observation carried forward, intention-to-treat population). *p<0.05 for liraglutide vs. insulin glargine and placebo. LEAD, liraglutide effect and action in diabetes. Reprinted with permission from Springer [29].